InMed Pharmaceuticals Inc.
For the period ended Jun 30, 2026. Filed Sep 9, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2026 · Filed Sep 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 2. Properties
Our corporate address is InMed Pharmaceuticals Inc., c/o Norton Rose Fulbright Canada LLP, Suite 1800 – 500 West Georgia Street, Vancouver, British Columbia, Canada V6B 0M3. The lease for our previous headquarters at Suite 1445 – 885 West Georgia Street, Vancouver, BC V6C 1B4 expired on August 31, 2026 and was not renewed.
The BayMedica facility lease was terminated effective August 31, 2026 as part of the subsidiary’s wind down.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.